HiFiBiO Therapeutics Drug Intelligence Science DIS® Platform Wins “AI Innovation of the Year” in 2023 BioTech Breakthrough Awards

Cambridge, MA, November 8, 2023 HiFiBiO Therapeutics, a clinical stage global biotech company with the goal of improving patient lives with single-cell precision, today announced that BioTech Breakthrough has named its proprietary translational platform, Drug Intelligence Science (DIS®) as the BioTech AI Innovation of the Year. The annual awards program features the best and brightest companies within the life sciences and biotechnology industries today.

The DIS® platform combines a proprietary microfluidic single-cell instrument with advanced AI/ML-based data analytics to gain unprecedented insights into human disease biology. Through the platform, HiFiBiO Therapeutics has advanced 8 programs to clinical candidate selection, including three programs that are currently in Phase 1 trials, a first-in-class TNFR2 agonist (HFB200301, NCT05238883), a best-in-class BTLA antagonist (HFB200603, NCT05789069), and a 2nd generation OX40 agonist (HFB301001, NCT05229601); all directed against DIS® selected advanced solid tumors.

“We are honored to have the DIS® platform recognized as Biotech Breakthrough’s AI Innovation of the Year,” commented Liang Schweizer, PhD, Founder, Chairperson, and CEO of HiFiBiO Therapeutics. “The award speaks to the underlying innovation and paradigm-shifting potential of the platform to increase the success of discovery and development of the most effective therapies for patients. Recently, I introduced our unique DIS® platform in an article published in Drug Discovery Today that highlights the important role our platform plays in translational research, and in turn, results for patients. HiFiBiO Therapeutics is committed to unleashing the power of this platform for drug discovery and development through its own internal programs and external collaborations.”

The mission of the annual BioTech Breakthrough Awards program is to honor excellence and recognize the creativity, hard work, and success of companies, technologies, and products within the field of biotechnology. This year’s program attracted more than 1,500 nominations from around the world.


About HiFiBiO Therapeutics

HiFiBiO Therapeutics is a clinical stage global biotech pioneering a unique high-resolution translational platform (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases which drives a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® platform and has been recognized as one of 2023’s Fierce 15 biotech companies. Additional information can be found at


HiFiBiO Therapeutics, HiFiBiO Therapeutics logo, and DIS® are trademarks of HiFiBiO and its affiliates.